TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11105328

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioperative magnesium
Number of subjects: 0
Study: 9392404

Group type: EXPERIMENTAL
Intervention: UNICEF group with restrictive fluid supplements and avoidance of bottles and pacifiers during the first 5 days of life
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard group with conventional feeding practice
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: UNICEF group
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 602
Study: 8156252

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 100 mg i.v. twice a day for 7 days followed by 400 mg orally three times a day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30
Study: 3784916

Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg oral micronised progesterone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 300 mg oral micronised progesterone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Percutaneous 17 beta-oestradiol 3 mg daily + 200 mg or 300 mg oral micronised progesterone
Number of subjects: 32
Study: 29241395

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT) administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27482015

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard intramedullary cutting jigs
Number of subjects: 133
Study: 24881859

Group type: EXPERIMENTAL
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 288
Study: 22262647

Group type: EXPERIMENTAL
Intervention: Fresh red blood cells (RBCs) transfusion
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Stored red blood cells (RBCs) transfusion (stored for 24.5 days)
Number of subjects: 35
Study: 19776372

Group type: EXPERIMENTAL
Intervention: SR1
Number of subjects: 32

Group type: COMPARATOR
Intervention: SR2
Number of subjects: 32
Study: 18766016

Group type: EXPERIMENTAL
Intervention: Unfamiliar one-part piano melodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unstructured note sequences
Number of subjects: 0
Study: 15930042

Group type: EXPERIMENTAL
Intervention: TNF-alpha 0.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TNF-alpha 1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TNF-alpha 2 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TNF-alpha 3/4 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All TNF-alpha doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher TNF-alpha doses
Number of subjects: 100
Study: 12027069

Group type: EXPERIMENTAL
Intervention: Biminne capsules (5 capsules twice a day for 12 weeks)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo (5 capsules twice a day for 12 weeks)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Biminne (dose-response study)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Biminne treatment
Number of subjects: 58
Study: 9500317

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin (trough blood concentrations of 75-125 ng/mL)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Normal-dose cyclosporin (trough blood concentrations of 150-250 ng/mL)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Low-dose cyclosporin
Number of subjects: 231

Group type: COMPARATOR
Intervention: Normal-dose cyclosporin
Number of subjects: 231
Study: 7886650

Group type: EXPERIMENTAL
Intervention: Fenoterol (100 micrograms/puff or 200 micrograms/puff)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fenoterol (200 micrograms)
Number of subjects: 18
Study: 3174273

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30601347

Group type: EXPERIMENTAL
Intervention: Altered oximetry (artificially increasing saturation 3% points above true values)
Number of subjects: 0

Group type: COMPARATOR
Intervention: True oximetry (true saturation values)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altered oximetry
Number of subjects: 0

Group type: COMPARATOR
Intervention: True oximetry
Number of subjects: 0
Study: 29392894

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 5
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 7
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide at pH 8.4
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide (all pH values)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (non-stained)
Number of subjects: 90
Study: 28676200

Group type: EXPERIMENTAL
Intervention: Cigar Box Arthroscopy Trainer (CBAT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anatomic Knee Arthroscopy Trainer (AKAT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (didactic training)
Number of subjects: 24
Study: 25775672

Group type: EXPERIMENTAL
Intervention: Viabahn endoprosthesis
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard balloon angioplasty
Number of subjects: 83
Study: 23736733

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lifestyle-intensive medical management
Number of subjects: 120
Study: 21989185

Group type: EXPERIMENTAL
Intervention: 4 cycles of anthracycline chemotherapy
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1000
Study: 19052541

Group type: EXPERIMENTAL
Intervention: Divalproex ER + Olanzapine
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Divalproex ER + Risperidone
Number of subjects: 402

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 402

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 402
Study: 17287823

Group type: EXPERIMENTAL
Intervention: NBI‐34041 (10, 50, or 100 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14766394

Group type: EXPERIMENTAL
Intervention: Spheramine (cultured human retinal pigment epithelial cells attached to microcarriers)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Spheramine
Number of subjects: 6
Study: 11136171

Group type: EXPERIMENTAL
Intervention: Serum cystatin C concentration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) measured using inulin clearance (C(in)) technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Plasma creatinine concentration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Correlation between serum cystatin C concentration and C(in)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: GFR less than the lower 95% confidence interval
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Serum cystatin C concentration greater than the upper 95% confidence interval
Number of subjects: 41
Study: 9082927

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7944433

Group type: EXPERIMENTAL
Intervention: Portal infusion chemotherapy (n=5)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Systemic chemotherapy (n=6)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Arterial infusion chemotherapy (n=8)
Number of subjects: 19
Study: 3984837

Group type: EXPERIMENTAL
Intervention: Cibenzoline (1.0 mg/kg IV, then 1 mg/kg increments to a maximum of 3.0 mg/kg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Procainamide (1000 mg IV, then 1500 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Chronic oral cibenzoline therapy (mean follow-up of 8.8 months)
Number of subjects: 33
Study: 30477827

Group type: EXPERIMENTAL
Intervention: 700 mg Zataria multiflora Boiss. (Shirazi thyme) powder twice daily for 12 weeks
Number of subjects: 85
Study: 27538497

Group type: EXPERIMENTAL
Intervention: DA9301 (1000 mg/day for 4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DA9301
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25306810

Group type: EXPERIMENTAL
Intervention: Disposable circumcision suture device (DCSD), n = 129
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional circumcision (CC), n = 120
Number of subjects: 249
Study: 22870258

Group type: EXPERIMENTAL
Intervention: Low skeletal muscle index
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Skeletal muscle index
Number of subjects: 174
Study: 19819914

Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel (group D)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel alternating with 3-weekly gemcitabine (group D/G)
Number of subjects: 237
Study: 18820037

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prefabricated shoe inserts
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prefabricated shoe inserts (after switching from custom orthoses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (after switching from prefabricated inserts)
Number of subjects: 42
Study: 17547312

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type‐A (BTX‐A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo saline injection
Number of subjects: 32
Study: 15077032

Group type: EXPERIMENTAL
Intervention: Nitric oxide inhalation (20 ppm administered 10 min after reperfusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo gas (administered 10 min after reperfusion)
Number of subjects: 20
Study: 10680840

Group type: EXPERIMENTAL
Intervention: VEGF plasmid/liposome (P/L) gene transfer (1000 microg of VEGF)
Number of subjects: 15

Group type: COMPARATOR
Intervention: beta-galactosidase plasmid/liposome (P/L) gene transfer (1000 microg of beta-galactosidase)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Ringer lactate (control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control angiography after 6 months
Number of subjects: 15
Study: 9377618

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 1655

Group type: COMPARATOR
Intervention: H2RAs (ranitidine, famotidine, cimetidine, roxatidine)
Number of subjects: 1655
Study: 8245283

Group type: EXPERIMENTAL
Intervention: Imipramine plus clinical management (IMI-CM)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Interpersonal psychotherapy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Pill placebo plus clinical management
Number of subjects: 250
Study: 4037168

Group type: EXPERIMENTAL
Intervention: AIR WISE asthma self-management program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study: 30415650

Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (sugar-coated tablet)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (film-coated tablet)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride 50 mg (both formulations)
Number of subjects: 36
Study: 29169170

Group type: COMPARATOR
Intervention: Open and double-blind placebo-controlled food challenges (DBPCFC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: HDM-induced asthma and anti-mite IgE levels
Number of subjects: 51
Study: 26414089

Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 29

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 29
Study: 22796389

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) application over the rectus femoris, vastus lateralis and vastus medialis muscles
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonelastic adhesive tape application over the rectus femoris, vastus lateralis and vastus medialis muscles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (10 min at rest)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) application
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nonelastic adhesive tape application
Number of subjects: 60
Study: 21127897

Group type: EXPERIMENTAL
Intervention: Stationary running on dry land
Number of subjects: 12

Group type: COMPARATOR
Intervention: Stationary running in water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Submaximal cadences
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Maximal velocity
Number of subjects: 12
Study: 19247757

Group type: EXPERIMENTAL
Intervention: Intranasal 5% lidocaine plus naphazoline solution 0.2 mg ml(‐1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Topical intranasal saline 20 ml (control group)
Number of subjects: 28
Study: 16426087

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 1800
Study: 15616477

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support model (supported employment)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Psychosocial rehabilitation program (transitional employment)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Standard services
Number of subjects: 176
Study: 10768245

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g i.v. 30 min preinterventionally
Number of subjects: 216

Group type: COMPARATOR
Intervention: No study medication (control group)
Number of subjects: 216
Study: 9357093

Group type: EXPERIMENTAL
Intervention: Valproic acid (500 mg sodium valproate) under fasting conditions (treatment A)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Valproic acid (500 mg sodium valproate) after ingestion of 14 g citrus pectin (treatment B)
Number of subjects: 12
Study: 8375437

Group type: EXPERIMENTAL
Intervention: In situ without stone manipulation
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Bypass stones with stent
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Placement of a catheter below stone with continuous saline irrigation
Number of subjects: 120
Study: 3081599

Group type: EXPERIMENTAL
Intervention: Cromolyn (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn (12 doses of 20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn (single dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30767715

Group type: EXPERIMENTAL
Intervention: Online opioid overdose prevention training (OOPT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: In-person opioid overdose prevention training (OOPT)
Number of subjects: 100
Study: 29098749

Group type: EXPERIMENTAL
Intervention: Food-specific go/no-go training
Number of subjects: 0

Group type: COMPARATOR
Intervention: General inhibitory control training
Number of subjects: 0
Study: 26723484

Group type: COMPARATOR
Intervention: Calcium Hydroxide (CH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation + Calcium Hydroxide (CH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TheraCal LC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser irradiation + TheraCal LC
Number of subjects: 60
Study: 24720924

Group type: EXPERIMENTAL
Intervention: Nonfatal cardiovascular events
Number of subjects: 2556

Group type: COMPARATOR
Intervention: No nonfatal cardiovascular events
Number of subjects: 2556
Study: 23167682

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20496791

Group type: EXPERIMENTAL
Intervention: Sporobakterin liquid, a suspension for oral use
Number of subjects: 38
Study: 18606726

Group type: EXPERIMENTAL
Intervention: Social-evaluative task (SET) condition
Number of subjects: 89

Group type: COMPARATOR
Intervention: Nonexplicitly evaluative conditions
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: SET condition
Number of subjects: 89
Study: 16098081

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a 180 mg/week with ribavirin for 48 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Peginterferon alpha-2a 180 mg/week without ribavirin for 48 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon/ribavirin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Undetectable RNA at 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Age <18 years
Number of subjects: 20
Study: 12164887

Group type: EXPERIMENTAL
Intervention: LifeSite System with 70% isopropyl alcohol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Tesio-Cath
Number of subjects: 104

Group type: COMPARATOR
Intervention: LifeSite System with 0.2% sodium oxychlorosene
Number of subjects: 104
Study: 10099040

Group type: EXPERIMENTAL
Intervention: Ceftibuten alone (400 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ceftibuten with antacid (Mylanta Double-Strength Liquid; 60 mL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ceftibuten with ranitidine (150 mg/12 hours after 3 days of dosing)
Number of subjects: 18
Study: 7706151

Group type: EXPERIMENTAL
Intervention: Subject-selected reinforcers
Number of subjects: 4

Group type: COMPARATOR
Intervention: Experimenter-selected reinforcers
Number of subjects: 4
Study: 2751753

Group type: EXPERIMENTAL
Intervention: pindolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 30
Study: 999412

Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (combined with CPZ)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alcohol (combined with sulpiride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31520242

Group type: EXPERIMENTAL
Intervention: Education about oximetry and viewing an oximeter during training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional paced breathing (no education or oximetry)
Number of subjects: 20
Study: 28273549

Group type: EXPERIMENTAL
Intervention: short-term tacrolimus (Tac) from -8 days to +30 days
Number of subjects: 174

Group type: COMPARATOR
Intervention: cyclosporine (CsA)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: short-term tacrolimus (Tac)
Number of subjects: 174
Study: 25666724

Group type: EXPERIMENTAL
Intervention: Metha™ femoral prosthesis
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nanos™ femoral prosthesis
Number of subjects: 50
Study: 23917662

Group type: EXPERIMENTAL
Intervention: Walking training (n=13)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (n=12)
Number of subjects: 29
Study: 20924607

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IVIG 0.5 g/kg at 12 h postnatal age
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg at 12 h postnatal age
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IVIG group (both doses)
Number of subjects: 90
Study: 19170847

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patch (TTP)
Number of subjects: 1094
Study: 16689842

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: No beta-blocker therapy (MI patients)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 38
Study: 15569910

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 220
Study: 11251672

Group type: EXPERIMENTAL
Intervention: Intensive education on lifestyle (diet, exercise, smoking) with polypharmacological treatment
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 160
Study: 9924378

Group type: EXPERIMENTAL
Intervention: tPA (10 micrograms)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control (anti-inflammatory drugs only)
Number of subjects: 86
Study: 7816294

Group type: EXPERIMENTAL
Intervention: Emla cream applied for at least 2 hours prior to injection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: rHuEpo alpha
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: rHuEpo beta
Number of subjects: 48
Study: 3140155

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium 4% ophthalmic solution (Opticrom)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (matching drug vehicle)
Number of subjects: 65
Study: 30540619

Group type: EXPERIMENTAL
Intervention: Task-oriented EMG-triggered electrical stimulation therapy for wrist/finger extensors in addition to conventional physical therapy for 5 sessions a week for 4 weeks.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional physical therapy for 20 sessions.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Task-oriented EMG-triggered electrical stimulation therapy.
Number of subjects: 27
Study: 30518430

Group type: EXPERIMENTAL
Intervention: NET intervention
Number of subjects: 1943

Group type: COMPARATOR
Intervention: Control (passive dissemination of guidelines)
Number of subjects: 1943
Study: 27131100

Group type: EXPERIMENTAL
Intervention: Dilute apple juice/preferred fluids (n=323)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Electrolyte maintenance solution (n=324)
Number of subjects: 647
Study: 24456217

Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg/day or 10 mg/day
Number of subjects: 152

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 152
Study: 22301846

Group type: EXPERIMENTAL
Intervention: RIPC+RIPostC (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (n=35)
Number of subjects: 70
Study: 20618936

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Activator instrument
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mobilisation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 47
Study: 17924246

Group type: EXPERIMENTAL
Intervention: Interpersonal counselling (IPC)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 117